In the initial cohort of 5 SMARCA4‐deficient uterine sarcomas described by Kolin et al [25], 4 cases had advanced stage disease (stage III or IV) while staging information was not available for the fifth case (though it likely was advanced in stage as only biopsy was performed and the patient succumbed to her disease 1 month after the biopsy), and the median survival was reported as 7 months (1–43 months). This evidence concerns the gene SMARCA4 and uterine corpus sarcoma.